key: cord-0735130-dny9rgv9 authors: Calabria, Elena; Canfora, Federica; Mascolo, Massimo; Varricchio, Silvia; Mignogna, Michele Davide; Adamo, Daniela title: Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review date: 2022-03-05 journal: Pathol Res Pract DOI: 10.1016/j.prp.2022.153834 sha: de436a505ea164459526381063436a307a04296d doc_id: 735130 cord_uid: dny9rgv9 BACKGROUND: Cases of severe autoimmune blistering diseases (AIBDs) have recently been reported in association with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. AIMS: To describe a report of oropharyngeal pemphigus vulgaris (OPV) triggered by the mRNABNT162b2 vaccine (Comirnaty®/ Pfizer/ BioNTech) and to analyze the clinical and immunological characteristics of the AIBDs cases reported following the SARS-CoV-2 vaccination. METHODS: The clinical and immunological features of our case of OPV were documented. A review of the literature was conducted and only cases of AIBDs arising after the SARS-CoV-2 vaccination were included. CASE REPORT: A 60-year old female patients developed oropharyngeal and nasal bullous lesions seven days after the administration of a second dose of the mRNABNT162b2 vaccine (Comirnaty®/ Pfizer/BioNtech). According to the histology and direct immunofluorescence findings showing the presence of supra-basal blister and intercellular staining of IgG antibodies and the presence of a high level of anti-Dsg-3 antibodies (80 U/ml; normal < 7 U/ml) in the serum of the patients, a diagnosis of oropharyngeal Pemphigus Vulgaris was made. REVIEW: A total of 35 AIBDs cases triggered by the SARS-CoV-2 vaccination were found (including our report). 26 (74.3%) were diagnosed as Bullous Pemphigoid, 2 (5.7%) as Linear IgA Bullous Dermatosis, 6 (17.1%) as Pemphigus Vulgaris and 1(2.9%) as Pemphigus Foliaceus. The mean age of the sample was 72.8 years and there was a predominance of males over females (F:M=1:1.6). In 22 (62.9%) cases AIBDs developed after Pfizer vaccine administration, 6 (17.1%) after Moderna, 3 (8.6%) after AstraZeneca, 3 (8.6%) after CoronaVac and (one was not specified). All patients were treated with topical and/or systemic corticosteroids, with or without the addition of immunosuppressive drugs, with a good clinical response in every case. CONCLUSION: Clinicians should be aware of the potential, though rare, occurrence of AIBDs as a possible adverse event after the SARS-CoV-2 vaccination. However, notwithstanding, they should encourage their patients to obtain the vaccination in order to assist the public health systems to overcome the COVID-19 pandemic. A number of vaccines have been developed to fight the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which still represents the major global public health issue. The vaccination campaign against the COVID-19 pandemic is crucial for health care systems and the risk-benefit ratio continues to be remarkably favorable [1] . However, different vaccine-related side effects have been reported, predominantly mild-to-moderate in severity, the most common being fatigue, muscle pain, headache, chills, a redness/swelling at the injection site, joint pain and fever. On the contrary, the incidence of severe adverse events, such as allergic reactions or anaphylaxis, is rare and ranges between 0.2 and 0.3% [2] . Additionally, various dermatological manifestations have been correlated with the administration of SARS-CoV-2 vaccines, ranging from local reactions, such as local swelling, erythema and delayed local hypersensitivity, to distal and/or generalized reactions, such as pruritus, urticaria, erythema multiforme, vasculitis and bullous diseases [3] . Interestingly, recent data suggests that the SARS-CoV-2 vaccines ma reactivate or even cause de novo autoimmune diseases, including hematological, neurological, rheumatic and dermatological diseases [3-4-5-6] . In this regard, cases of autoimmune blistering diseases (AIBDs), triggered by the SARS-Cov-2 vaccination, have recently been reported [7] [8] . AIBDs are rare and potentially life-threatening diseases affecting the mucous membranes and skin, whose pathogenesis is mediated by an antibody-response against the structural proteins of the desmosome or basement membrane zone of the stratified epithelia, resulting in the formation of blisters. Based on the clinical, histological and immunological features, two principal subgroups of AIBDs have been recognized: the intra-epithelial group, which includes Pemphigus Vulgaris (PV), Pemphigus Foliaceus (PF), Pemphigus Vegetans , Pemphigus Herpetiformis, IgA Pemphigus and IgG/IgA Pemphigus; and the sub-epithelial group, which includes Bullous Pemphigoid (BP), Mucous Membrane Pemphigoid, Pemphigoid Gestationis, anti-p200 Pemphigoid, Lichen Planus Pemphigoides, Epidermolysis Bullosa Acquisita and Linear Immunoglobulin A Bullous Dermatosis (LABD) [9] . Several factors, including genetic susceptibility and certain drugs, have been reported to trigger AIBDs [EGAMI] . However, the onset of these diseases after antiviral/antibacterial vaccination has been exceptionally rare with only a few cases reported before the COVID-19 period [10] . Herein we present a new case report of PV after SARS-Cov-2 vaccination and a review of the literature of all the AIBDs cases developed after COVID-19 vaccine administration. Demographic, clinical and immunological data were collected in relation to the case of the patient diagnosed with oropharyngeal pemphigus vulgaris (OPV) following an anti-SARSCov-2 vaccine at our department of Oral Medicine, University of Naples "Federico II". Written informed consent was obtained from the patient. Vegetans" OR "Pemphigus Herpetiformis" OR "IgA Pemphigus" OR "Bullous Pemphigoid" OR "Mucous Membrane Pemphigoid" OR Pemphigoid OR "Lichen Planus Pemphigoides" OR" Epidermolysis bullosa acquisita" OR "Linear Immunoglobulin A bullous dermatosis" OR "dermatological manifestation*" OR "dermatological complication*" OR "dermatological reaction*" OR "dermatological adverse event*" OR "cutaneous manifestation*" OR "cutaneous complication*" OR "cutaneous reaction*" OR "cutaneous adverse event*" OR "cutaneous side effect*" OR "skin reaction*" OR "skin manifestation*" OR "skin complication*" OR "skin adverse event*") The current literature was analyzed and all the case reports of AIBDs correlated to the anti-SARSCov-2 vaccination were included, based on the following criteria i) typical clinical findings of bullous and/ or erosive lesions affecting the mucosal surfaces (oropharyngeal, genital and nasal etc.), and/or the skin; (ii) histopathological specimens exhibiting intra-epithelial or sub-epithelial J o u r n a l P r e -p r o o f detachment; and iii) at least one immunological evidence of autoantibody response, via direct immune-fluorescence microscopy (DIF) and/or serological detection of serum autoantibodies by indirect immune-fluorescence microscopy (IIF) and/or enzyme-linked immunosorbent assay (ELISA Test) [9, 11] . Cases of presumable AIBDs were excluded in case of negativity of DIF, IIF and ELISA Test, or if none of them was tested. The title, abstracts and the full texts of the case reports were independently screened by two authors (EC and CF) and a third reviewer (AD) resolved disagreements. Descriptive statistics were used to detail clinical characteristics of the patients. In case of normally distributed variables means, standard deviation and range were used, otherwise median and interquartile ranges. For categorical data, percentages were displayed. A female patient, 60 years old, was referred to the Oral Medicine Unit of the University of Naples "Federico II" on account of the occurrence of painful oropharyngeal and nasal lesions which had lasted for more than five months. Her past history revealed that the lesions had appeared seven days following the administration of a second dose of the mRNABNT162b2 vaccine (Comirnaty®/ Pfizer/BioNtech) (Figure 1 ). The oral lesions had been stable for three months before the diagnosis and the patient had not developed cutaneous lesions. A perilesional biopsy of the mandibular gingiva was taken. Histology showed a partially ulcerated mucosa covered with only one or more layers of keratinocytes aligned along the basement membrane. At one edge of the biopsy, the nonkeratinizing squamous cell epithelium showed severe acantholysis, forming a suprabasal blister with a row of "gravestone" looking basal cells attached to the connective tissue. There was a moderate band-like lymphocytic infiltrate in the subepithelial chorion, with some eosinophils and several small vessels. (Figure 2 A-C) . A diagnosis of bullous mucositis, as PV, was made. Direct immunofluorescence revealed intercellular staining of IgG antibodies, confirming the diagnosis of pemphigus Vulgaris (Figure 2 D) . The patient's serum presented a high level of anti-Dsg-3 antibodies (80 U/ml; normal < 7 U/ml) while the anti-Dsg-1 antibodies titer was within the limits (4.4U/ml; normal <14 U/ml). Therefore, a diagnosis of OPV after SARS-CoV-2 vaccination was made, taking into account the timing of the onset of the bullous lesions. The patient was promptly treated with immunosuppressive therapy consisting in high dose corticosteroids (1mg of prednisone J o u r n a l P r e -p r o o f per kg of body weight) for six weeks without achieving a satisfactory disease control. Indeed, due to the onset of dysphagia with a consequent difficulty in eating and drinking, further therapy with a monoclonal antibody anti-CD20, namely Rituximab, was scheduled (prescribed according to the rheumatoid arthritis protocol at a dose of 1000 mg twice at 2-week intervals [12] ). This treatment resulted in an overall improvement in the patient's condition within three weeks. She is currently in partial clinical remission and undergoing follow-up in our department. A total of 195 articles was retrieved and after the screening, 20 articles were finally included for the review. A total of 35 AIBDs cases (including our case) were found, as shown in Table 1 The current literature review summarizes the cases of AIBDs following an anti-SARS-Cov-2 vaccination published so far, reporting demographic, clinical and immunological characteristics of J o u r n a l P r e -p r o o f the patients. To the best of our knowledge, this is the fifth case of PV developing after SARS-Cov-2 vaccination. During our research, we found a total of 35 case-reports of patients with clinical and immunological diagnosis of AIBDs, however, the number may be even higher as there are, in fact, few case-reports published in the current literature with a diagnosis of AIBDs based on clinical findings [7] . In this case-series, the sub-epithelial diseases represented the majority of the cases (80.0%), especially the BP type, followed by the intraepithelial disease (20.0%). The median ages of AIBDs onset in these patients did not differ from those reported for the spontaneous forms [6] . Interestingly, males were more affected than females (F:M=1:1.7) especially in the sub-epithelial group (F:M=1:2.1). Conversely, no gender difference has been reported in respect of any of pemphigoid diseases occurring spontaneously [6] . Notably, almost the 62.5% of the AIBDs cases developed after Pfizer vaccine administration. This figure may possibly be explained in terms of the more frequent use of the Pfizer vaccine compared to the others, as it has been administered to 28% of the population compared to the Moderna vaccine (18%) and the AstraZeneca (12%) [31] . AIBDs developed after either the first, the second and third administration of the vaccine, and, in some cases, the bullous lesions either worsened or reactivated in patients receiving the second dose. Altogether, these findings suggest the potential association between new-onset AIBDs and COVID-19 vaccine, which may enhance or even trigger the immunological response, as also reported in other autoimmune diseases [32] [33] . Virus-or vaccine-associated autoimmunity is a well-known phenomenon as many viruses have been proposed to trigger a variety of autoimmune responses [34] , as well as vaccines due to either the cross-reactivity between antigens or the effect of adjuvant [35] . One of the most accredited hypotheses is based on the cross-reaction between antibodies anti-SARS-CoV-2 pike glycoproteins with structurally similar host peptide protein sequences due to a molecular mimicry mechanism [36] . It may be speculated also that susceptible individuals with a pre-existing predisposition to autoimmune/autoinflammatory dysregulation may present a higher risk of immunological side effects after the administration of such vaccines, some of which contains nucleic acids [35] . Nonetheless, a cause-effect relationship cannot be established, although the presence of a temporal correlation may be suggestive of this event [37] . It is of upmost importance to increase awareness of this potential adverse effect related to the SARS-CoV-2 vaccination and, therefore, to promote the report of other cases for a better understanding of the phenomenon. In this regard, clinicians should carefully weigh the potential side effects of the vaccine against the well described severe complications of the SARS-CoV-2 infection. Indeed, although diseases flares of already diagnosed AIBDs have been documented, the occurrence of AIBDs post-vaccination is overall a rare event and, according to this review's data, the disease can be safely controlled with immune-suppressive therapies. Therefore, clinicians J o u r n a l P r e -p r o o f The Impact of COVID-19 Vaccination on the Italian Healthcare System: A Scenario Analysis Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination Skin reactions to COVID-19 vaccines: An American Academy of Dermatology/International League of Dermatological Societies registry update on reaction location and COVID vaccine type New-Onset Systemic Lupus Erythematosus after mRNA SARS-CoV-2 Vaccination. Case Rep Rheumatol ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review New-onset autoimmune phenomena post-COVID-19 vaccination Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination Oral pemphigus after COVID-19 vaccination Autoimmune bullous skin diseases, pemphigus and pemphigoid Blistering autoimmune skin reaction following SHINGRIX vaccination in an ulcerative colitis patient: Case report and literature review. Vaccine Diagnosis and management of pemphigus: Recommendations of an international panel of experts Food and Drug Administration Rituxan label Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2 Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient An unusual presentation of pemphigus foliaceus following COVID-19 vaccination Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review Epub ahead of print Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine Epub ahead of print A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine Bullous pemphigoid after SARS-CoV-2 vaccination: Spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies Bullous pemphigoid and COVID-19 vaccine Case of bullous pemphigoid following coronavirus disease 2019 vaccination New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center Epub ahead of print Pemphigus vulgaris after SARS-CoV-2 vaccination: a case with new-onset and two cases with severe aggravation COVID-19) Dashboard The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated? Autoimmune-and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination. Blood Adv Covid-19 and autoimmunity Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review